Connecticut Agricultural Experimental Station

Connecticut Agricultural Experimental Station, a U.S. state government entity headquartered in New Haven, Connecticut, acts as a prime recipient for federal grants and as a contractor for federal purchase orders in agricultural research, food safety testing, and forest health monitoring. The station performs applied and basic research spanning invasive species detection and management, plant and animal disease control, vector-borne pathogen surveillance, and chemical food safety testing across Connecticut and subordinate field sites.

The station's customer base is concentrated in USDA agencies. The Department of Agriculture Animal and Plant Health Inspection Service leads by award count (90 awards), followed by the National Institute of Food and Agriculture across multiple program streams (105 combined awards across AFRI, Hatch Act, and McIntire-Stennis mechanisms). The Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh has awarded five purchase orders totaling $1.3 million for fall acaricide research targeting Ixodes scapularis tick suppression and pollinator evaluation. Environmental Protection Agency and the National Institute of Allergy and Infectious Diseases round out the active customer set. Award concentration by dollar value tracks closely with volume — USDA dominates both metrics — though CDC's recent tick-focused work anchors most potential value outside the agricultural portfolio.

Recent prime grant work exemplifies the station's applied research posture. NIFA awarded $728 thousand for nanotechnology-based fire blight control in apple and pear using essential oil-loaded nanoclay systems; $1.65 million under the Hatch Act Capacity Program for risk-informed land management, vector ecology, and soil microbiology research; and $639 thousand under the McIntire-Stennis Cooperative Forestry Research program for forest health and urban forestry work including biological control of hemlock woolly adelgid and beech leaf disease monitoring. The FDA awarded a $1.44 million Cooperative Agreement under the Laboratory Flexible Funding Model for human and animal food product chemical testing, establishing the station as Connecticut's sole laboratory for the Milk and Fluid Milk Replacer Surveillance Program. APHIS funding streams dominate by count, supporting annual exotic pest and disease surveillance across commodities including nursery stock, Christmas trees, vineyards, and aquatic plants, plus tick and mosquito surveillance for vector-borne pathogen monitoring.

The station acts as sub-recipient on university-led grants with Cornell University, Yale University, University of Connecticut, Texas Tech University, and others, performing specialized analytical work, greenhouse and field trials, surveillance, and sample analysis. Recent sub-award work includes population genetics analyses of Aedes aegypti mosquitoes for vector competence research under Yale direction, wastewater analysis for illicit drug surveillance under Yale's NIH funding, and fungal screening and field trials for ectomycorrhizal research under Yale collaboration. The station's role in sub-awards emphasizes hands-on research execution and analytical capability provision rather than coordination.

Activity has grown unevenly. The station recorded 14 awards in 2022, 15 in 2023, 29 in 2024, then 19 in 2025 and 16 through August 2026. Nineteen awards reach completion within the next twenty-four months, representing recompete exposure concentrated in APHIS pest surveillance cooperative agreements and NIFA grant mechanisms. The station competes full-and-open across all customer agencies with no set-aside designation evident in the source material. Grant mechanisms dominate the portfolio — formula grants (Hatch, McIntire-Stennis) and project grants (AFRI, NIAID, NSF) comprise the majority of prime awards, with cooperative agreements from APHIS and FDA as secondary mechanisms. Two recent CDC purchase orders (August 2023 and August 2026, each under $250 thousand) represent the sole contract vehicle in the visible prime footprint, with both firm fixed-price and ultimate completion dates of July 2029.